NASDAQ$SIBN

SI-BONE Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Reported financial results for the first quarter of 2020.

SI-BONE, Inc. reported a 12% increase in revenue to $16.8 million for Q1 2020, with U.S. revenue up 14% to $15.3 million. The company's operating loss was $11.9 million, and net loss was $12.8 million, or $0.47 per diluted share.

  • Revenue of $16.8 million for the first quarter 2020, representing a 12% increase over the corresponding period in 2019
  • U.S. revenue of $15.3 million for the first quarter 2020, representing a 14% increase over the corresponding period in 2019
  • Received FDA 510(k) clearance for an expanded indication for the iFuse Implant System to support the Company's trauma program
  • Obtained positive coverage by Health Alliance Plan, a commercial payor in Michigan

Headline financials

Total Revenue

$16.8M

Previous: $15M+12.2%
EPS (adj)

-$0.47

Previous: -$0.38-23.7%
Gross margin

89.0%

Previous: 90.0%-1.1%
Capital Expenditures

-$884K

Previous: -$412K-114.6%
Free Cash Flow

-$13.7M

Previous: -$9.76M-40.0%
Net Income

-$12.8M

Previous: -$9.35M-36.7%
Operating Income

-$11.9M

Previous: -$8.8M-35.0%
Gross Profit

$14.9M

Previous: $13.5M+10.6%
Cash & Equivalents

$67.6M

Previous: $12.6M+437.9%
Total Assets

$168M

Previous: $132M+27.1%

Revenue & EPS history

SI-BONE · Revenue · Quarterly

$16.8M

Q1 2020+12.2%vs Q1 2019
Beat estimate in 8 of 10 quarters(80%)
ActualEstimate

Forward guidance

Due to the evolving environment and continued uncertainties from the impact of COVID-19, SI-BONE has withdrawn its previously announced guidance for the full year 2020.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

-1.8%

Avg return

Earnings day

-1.3%

Avg return

5 days after

-0.8%

Avg return

30 days after

40%

12 / 30 earnings

Positive

+16.2%

Q4 2022

Best reaction

-23.7%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.3%+15.3%
Q4 2025-1.0%-0.6%-17.8%
Q3 2025+16.1%+11.1%+20.0%
Q1 2025+15.6%+29.8%+33.8%
Q4 2024+5.6%+3.7%-19.9%
Q3 2024-17.5%-18.8%-14.5%
Q2 2024-3.6%-5.2%+10.2%
Q1 2024+10.4%+8.0%-1.1%
Q4 2023-12.4%-15.7%-22.0%
Q3 2023-4.7%-12.4%-0.9%
Q2 2023-12.5%-9.6%-7.1%
Q1 2023+9.6%-0.3%+13.9%
Q4 2022+16.2%+19.5%+14.0%
Q3 2022-23.1%-16.4%-26.5%
Q2 2022-6.4%+0.1%+3.5%
Q1 2022-23.7%-27.6%-12.2%
Q4 2021+2.4%+3.2%+3.2%
Q3 2021-7.8%-10.9%-13.6%
Q2 2021-15.1%-18.9%-18.3%
Q1 2021-7.0%-7.5%-17.2%
Q4 2020+4.0%+6.6%+8.3%
Q3 2020+3.2%+0.5%+10.7%
Q2 2020+13.6%+17.7%+31.7%
Q1 2020+9.0%+11.9%+16.3%
Q4 2019-11.9%-21.7%-28.9%
Q3 2019-4.4%-4.5%-0.6%
Q2 2019+6.8%+10.7%+11.3%
Q1 2019-3.9%-8.1%-1.5%
Q4 2018-4.6%-3.6%-9.4%
Q3 2018-3.0%+4.8%+10.5%
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q1 2016
Q1 2015
Q4 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro